J. Bader

发表

A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis

B. Law, M. Sedláčková, P. Vaňhara, 2019, Haematologica.

Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.

M. Kraus, J. Bader, C. Driessen, 2014, Leukemia research.

Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.

B. Xin, L. Besse, A. Bešše, 2019, Cell chemical biology.

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

H. Rosing, C. Berset, H. Hawle, 2016, Haematologica.

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance

H. Overkleeft, H. Overkleeft, M. Kraus, 2013, Blood Cancer Journal.

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

A. Kisselev, Nora Liu, J. Kraus, 2015, Cancer Chemotherapy and Pharmacology.

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

T. Silzle, L. Besse, A. Bešše, 2017, Blood Cancer Journal.

Selective Inhibition of the proteasome's β2 Catalytic Subunit Alone Does Not Induce Cytotoxicity, but Resensitizes Bortezomib-Refractory Myeloma Cells for Bortezomib Treatment

H. Overkleeft, P. Geurink, M. Kraus, 2011 .

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

H. Rosing, H. Hawle, A. Huitema, 2016, Haematologica.

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

B. Everts, B. Florea, H. den Dulk, 2016, Leukemia.